Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly as a result of chemotherapy resistance and numerous somatic mutations. Consequently, PDAC is a prime candidate for the use of sequencing to identify causative mutations, facilitating subsequent administration of targeted therapy. In a feasibility study, we retrospectively assessed the therapeutic recommendations of a novel, evidence‐based software that analyzes next‐generation sequencing (NGS) data using a large panel of pharmacogenomic biomarkers for efficacy and toxicity. Tissue from 14 patients with PDAC was sequenced using NGS with a 620 gene panel. FASTQ files were fed into treatmentmap. The results were compared with chemotherapy in the patients, including all side effects. No changes in therapy were made. Known driver mutations for PDAC were confirmed (e.g. KRAS, TP53). Software analysis revealed positive biomarkers for predicted effective and ineffective treatments in all patients. At least one biomarker associated with increased toxicity could be detected in all patients. Patients had been receiving one of the currently approved chemotherapy agents. In two patients, toxicity could have been correctly predicted by the software analysis. The results suggest that NGS, in combination with an evidence‐based software, could be conducted within a 2‐week period, thus being feasible for clinical routine. Therapy recommendations were principally off‐label use. Based on the predominant KRAS mutations, other drugs were predicted to be ineffective. The pharmacogenomic biomarkers indicative of increased toxicity could be retrospectively linked to reported negative side effects in the respective patients. Finally, the occurrence of somatic and germline mutations in cancer syndrome‐associated genes is noteworthy, despite a high frequency of these particular variants in the background population. These results suggest software‐analysis of NGS data provides evidence‐based information on effective, ineffective and toxic drugs, potentially forming the basis for precision cancer medicine in PDAC.

[1]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[2]  J. Ferlay,et al.  More deaths from pancreatic cancer than breast cancer in the EU by 2017 , 2016, Acta oncologica.

[3]  I. Elmaci,et al.  A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme , 2016, Biochemical Genetics.

[4]  David N. Rider,et al.  Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[5]  A. Bhaw-Luximon,et al.  Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification , 2016, Journal of Cancer Research and Clinical Oncology.

[6]  R. Feldman,et al.  Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. , 2016, Journal of gastrointestinal oncology.

[7]  P. Catalano,et al.  Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer , 2016, American journal of clinical oncology.

[8]  Q. Peng,et al.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review) , 2015, International journal of oncology.

[9]  E. Knudsen,et al.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. , 2016, Gastroenterology.

[10]  S. Linardopoulos,et al.  Aurora Kinase Inhibitors: Current Status and Outlook , 2015, Front. Oncol..

[11]  K. Offit,et al.  Identification of germline genetic mutations in patients with pancreatic cancer , 2015, Cancer.

[12]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[13]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[14]  E. Chiorean,et al.  Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies , 2015, Drug design, development and therapy.

[15]  F. Sinicrope,et al.  Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer , 2015, Current Treatment Options in Oncology.

[16]  M. Hidalgo,et al.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies , 2015, Nature Reviews Clinical Oncology.

[17]  M. Stratton,et al.  High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.

[18]  David M. Thomas,et al.  Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial , 2015, Clinical Cancer Research.

[19]  M. Choti,et al.  Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer , 2015, Oncotarget.

[20]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[21]  J. Bendell,et al.  Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Sunil Sharma,et al.  N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012 , 2015, Oncoscience.

[23]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[24]  F. Sotgia,et al.  Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease , 2015, Oncotarget.

[25]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Leary,et al.  The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges , 2015, Chinese journal of cancer.

[27]  A. Rademaker,et al.  The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria , 2014, Cancer.

[28]  J. Löhr.  Pancreatic cancer should be treated as a medical emergency , 2014, BMJ : British Medical Journal.

[29]  Razelle Kurzrock,et al.  Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.

[30]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[31]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[32]  T. Wilt,et al.  Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. , 2014, Journal of the National Cancer Institute.

[33]  J. Berlin,et al.  Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer , 2014, Cancer medicine.

[34]  D. Theodorescu,et al.  Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer , 2014, PloS one.

[35]  K. Goss,et al.  Exploiting APC function as a novel cancer therapy. , 2014, Current drug targets.

[36]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[37]  J. Taieb,et al.  FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study , 2014, BMC Cancer.

[38]  P. Stephens,et al.  Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms , 2013, Cancer cytopathology.

[39]  Jun Chen,et al.  Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells , 2013, Molecular Biology Reports.

[40]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[41]  S. Ellard,et al.  Clinical Applications of Next‐Generation Sequencing: The 2013 Human Genome Variation Society Scientific Meeting , 2013, Human mutation.

[42]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[43]  Ian H Kerridge,et al.  The economic evaluation of personalised oncology medicines: ethical challenges , 2013, The Medical journal of Australia.

[44]  J. Pearson,et al.  Clinical and molecular characterization of HER2 amplified-pancreatic cancer , 2013, Genome Medicine.

[45]  K. Offit,et al.  Identification of germline genetic mutations in patients with pancreatic adenocarcinoma. , 2013 .

[46]  F. Cappuzzo,et al.  Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure , 2013, BJU international.

[47]  H. Friess,et al.  [S3-guideline exocrine pancreatic cancer]. , 2013, Zeitschrift fur Gastroenterologie.

[48]  C. Crane.  Is Personalization of Care Coming to Pancreatic Oncology? , 2013, Annals of Surgical Oncology.

[49]  J. Carpten,et al.  Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples , 2012, PloS one.

[50]  T. Gress,et al.  Current concepts and novel targets in advanced pancreatic cancer , 2012, Gut.

[51]  E. Van Cutsem,et al.  Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[53]  Elaine R. Mardis,et al.  Applying next-generation sequencing to pancreatic cancer treatment , 2012, Nature Reviews Gastroenterology &Hepatology.

[54]  H. Mody,et al.  Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. , 2012, Cancer letters.

[55]  M. Kubo,et al.  Clinical applications of next-generation sequencing. , 2012, Clinical advances in hematology & oncology : H&O.

[56]  T. Gress,et al.  Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid , 2012, Gut.

[57]  F. Innocenti,et al.  Systemic therapies for pancreatic cancer--the role of pharmacogenetics. , 2012, Current drug targets.

[58]  C. Schmoor,et al.  Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer , 2012, British Journal of Cancer.

[59]  Michael J. Becich,et al.  Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics , 2012, Journal of pathology informatics.

[60]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Robson,et al.  An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. , 2011, The oncologist.

[62]  T. Conroy,et al.  Metastatic pancreatic cancer: old drugs, new paradigms , 2011, Current opinion in oncology.

[63]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[64]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[65]  V. Pankratz,et al.  Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non–Small Cell Lung Cancer Treated with Chemotherapy , 2011, Clinical Cancer Research.

[66]  J. Shipley,et al.  Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer: A Phase II Study , 2009, American journal of clinical oncology.

[67]  Zhiwei Wang,et al.  Pancreatic cancer: understanding and overcoming chemoresistance , 2011, Nature Reviews Gastroenterology &Hepatology.

[68]  A. Lipton,et al.  Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer , 2010, Journal of clinical gastroenterology.

[69]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[70]  Riccardo Spinelli,et al.  Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Fucini,et al.  The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model , 2009, Molecular Cancer Therapeutics.

[72]  M. Pino,et al.  Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers , 2009, Oncology.

[73]  P. Stenson,et al.  The Human Gene Mutation Database: 2008 update , 2009, Genome Medicine.

[74]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[75]  T. Okumura,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007, British Journal of Cancer.

[76]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[77]  M. Löhr.  Is it possible to survive pancreatic cancer? , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[78]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.

[79]  Wooin Lee,et al.  Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. , 2005, The oncologist.

[80]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  D. Iannitti,et al.  Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu , 2004 .

[82]  H. Lenz,et al.  Implications of Genetic Testing in the Management of Colorectal Cancer , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[83]  J. Nemunaitis,et al.  A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer , 2002, British Journal of Cancer.

[84]  H. Juhl,et al.  Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. , 2001, International journal of surgical investigation.

[85]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.